CSPC Pharmaceutical Gains Approval for New Diabetes Drug

CSPC Pharmaceutical Group has announced the receipt of marketing approval from China’s National Medical Products Administration for its new chemical drug, Prusogliptin Tablets, branded as Shanzeping. This innovative drug is designed to enhance insulin secretion and lower blood glucose levels, providing a new treatment option for adults with type 2 diabetes. The approval of Shanzeping not only marks a significant milestone for CSPC Pharmaceutical Group in the field of metabolic diseases but also enriches the company’s product portfolio. CSPC Pharmaceutical Group, based in Hong Kong, specializes in the development and production of pharmaceutical products, with a focus on innovative drugs and healthcare solutions.